Search

Abstract: Oxytetracycline (OTC) is used worldwide to protect crops against bacterial diseases. The US Environmental Protection Agency approved its use in apple, pear, nectarine, and peach, and set residue tolerance at 350ngg−1. A europium-sensitised luminescence (ESL) method was developed for in-situ determination of OTC residue in these fruits. After extraction in Na2EDTA-NaCl-McIlvaine buffer at pH 4 and filtration, cleanup was performed using hydrophilic-lipophilic balance cartridges. ESL was measured using a portable time-resolved fluorometer. The signal responded linearly over three orders of magnitude (10–10000ngg−1) with 17–50ngg−1 limits of quantitation and 2% averaged relative standard deviation. Recoveries were 84% and 82% at 100 and 350ngg−1, respectively. Inter-laboratory validation was performed by HPLC–MS/MS. [Copyright &y& Elsevier]

In this article the author discusses the impact of the seminal work of Stern and coauthors with the development of integrated pest management system in the U.S. It notes that the conservation of natural enemies to control secondary pests, combined with pesticides contributed to the success of IPM systems in western orchards. It looks on the result of the mandated changes in the use of pesticide prompted by the Food Quality Protection Act of 1996.

African Americans suffer a higher prevalence of hypertension compared with other racial/ethnic groups. In this study, we performed a pharmacogenomic genome-wide association study of blood pressure (BP) response to β-blockers in African Americans with uncomplicated hypertension. Genome-wide meta-analysis was performed in 318 African American hypertensive participants in the 2 Pharmacogenomic Evaluation of Antihypertensive Responses studies: 150 treated with atenolol monotherapy and 168 treated with metoprolol monotherapy. The analysis adjusted for age, sex, baseline BP and principal components for ancestry. Genome-wide significant variants with P<5×10(-8) and suggestive variants with P<5×10(-7) were evaluated in an additional cohort of 141 African Americans treated with the addition of atenolol to hydrochlorothiazide treatment. The validated variants were then meta-analyzed in these 3 groups of African Americans. Two variants discovered in the monotherapy meta-analysis were validated in the add-on therapy. African American participants heterozygous for SLC25A31 rs201279313 deletion versus wild-type genotype had better diastolic BP response to atenolol monotherapy, metoprolol monotherapy, and atenolol add-on therapy: -9.3 versus -4.6, -9.6 versus -4.8, and -9.7 versus -6.4 mm Hg, respectively (3-group meta-analysis P=2.5×10(-8), β=-4.42 mm Hg per variant allele). Similarly, LRRC15 rs11313667 was validated for systolic BP response to β-blocker therapy with 3-group meta-analysis P=7.2×10(-8) and β=-3.65 mm Hg per variant allele. In this first pharmacogenomic genome-wide meta-analysis of BP response to β-blockers in African Americans, we identified novel variants that may provide valuable information for personalized antihypertensive treatment in this group., (© 2016 American Heart Association, Inc.)